Health Care & Life Sciences » Pharmaceuticals | C4X Discovery Holdings PLC

C4X Discovery Holdings PLC | Cash Flow

Fiscal year is August-July. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
481.00
1,118.00
3,064.00
5,321.00
6,782.00
1,135
Depreciation, Depletion & Amortization
14.00
13.00
26.00
88.00
179.00
188
Other Funds
104.00
199.00
441.00
641.00
150.00
583
Funds from Operations
571.00
906.00
3,479.00
5,874.00
6,753.00
364
Changes in Working Capital
24.00
72.00
291.00
124.00
190.00
45
Net Operating Cash Flow
595.00
834.00
3,188.00
5,998.00
6,563.00
409
Capital Expenditures
14.00
7.00
93.00
92.00
91.00
Net Investing Cash Flow
14.00
7.00
93.00
159.00
91.00
Issuance/Reduction of Debt, Net
1,475.00
-
30.00
-
-
Net Financing Cash Flow
1,475.00
-
10,093.00
-
11,357.00
Net Change in Cash
866.00
841.00
6,812.00
6,157.00
4,703.00
Free Cash Flow
609.00
841.00
3,273.00
6,040.00
6,603.00
Net Assets from Acquisitions
-
-
-
67.00
-
Change in Capital Stock
-
-
10,123.00
-
11,357.00

About C4X Discovery Holdings

View Profile
Address
Manchester One
Manchester Greater Manchester M1 3LD
United Kingdom
Employees -
Website http://c4xdiscovery.com/
Updated 07/08/2019
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. Its software platforms consists of Taxonomy3, which utilizes a mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases; and Conformetrix, which determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.